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Background: Once a month, patients with multiple myeloma received an infusion of 
bisphosphonates, principally to reduce osteoclastic bone resorption. Recommended infusion time 
for pamidronate is 2 hours in the US and 4 hours in Europe because of its potential nephrotoxicity. 
From 2003, a 90 mg infusion of pamidronate was provided over 1 hour to patients with no 
pre-existing renal impairment, in the Daily Care Unit at Uddevalla Hospital.
Method: Retrospective analysis of the renal deterioration, serum calcium, and adverse effects 
in patients with multiple myeloma treated with 1-hour pamidronate 90 mg infusion from January 
2003 to April 2007.
Results: Seventy-nine patients provided valuable data. A total number of 846 infusions were 
given and the median number of infusion to each patient was 11. Signiﬁ  cant creatinine eleva-
tion was seen in 7 patients (8.9%), after 19 infusions (2.2%). Renal deterioration occurred in 
5 of these 7 patients, which was related to progress of the myeloma or opportunistic infections. 
Prevalence of infusion-related events was 0.8% and the mean total S-Ca was 0.05 mmol/L 
lower than the baseline.
Conclusion: Few events of renal deterioration, hypocalcemia, or other adverse effects resulted 
from a 1-hour pamidronate 90 mg infusion for multiple myeloma patients with no pre-existing 
renal impairment.
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Introduction
Multiple myeloma is a B cell malignancy characterized by osteolytic bone destruction 
resulting from asynchronous bone turnover, that is, the increased osteoclastic resorption 
of bone is not accompanied by increased bone formation (Kanis et al 1991; Berenson 
et al 2007). Bone disease can lead to bone pain, diffuse osteopenia, focal lytic lesions, 
pathologic fractures, spinal cord compression, and hypercalcemia, and is a major cause 
of morbidity and mortality in patients with myeloma (Yeh and Berenson 2006).
Bisphosphonates, in the form of pamidronate and zoledronic acid, which have 
been validated as adjunctive therapy in the prevention and treatment of myeloma 
bone disease, inhibit osteoclastic activity and are effective in the treatment of cancer 
associated hypercalcemia (Berenson et al 1996). The second-generation bisphospho-
nate, pamidronate (pamidronate disodium), is a potent inhibitor of bone absorption 
at doses that do not affect bone mineralization, and is now a mainstay of myeloma 
therapy (Kellihan and Mangino 1992; Berenson et al 1996). The most effective dose 
for normalizing serum calcium concentrations in a dose-ranging trial in patients with 
cancer-associated hypercalcemia was found to be 90 mg of pamidronate (Nussbaum 
et al 1993). For multiple myeloma patients with bone disease and no pre-existing renal 
impairment, newly updated guidelines (Lacy et al 2006; Kyle et al 2007) recommend an 
intravenous pamidronate 90 mg infusion delivered over at least 2 hours or zoledronic 
acid 4 mg delivered over 50 minutes every 3 to 4 weeks for 2 years. Reducing the Therapeutics and Clinical Risk Management 2008:4(6) 1372
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initial pamidronate dose is recommended for patients with 
pre-existing renal insufﬁ  ciency.
Intravenous bisphosphonates are eliminated almost 
exclusively by the kidneys; this elimination is dependent on 
the patient’s creatinine clearance (Mehrotra and Ruggiero 
2006). Pamidronate-induced renal deterioration depends 
on dose, and infusion time. It usually occurs with doses 
over 180 mg (Markowitz et al 2001; Desikan et al 2002; 
Markowitz et al 2002) rather than infusion time of less than 
2 hours (Leyvraz et al 1992; Janssen et al 2001; Lockridge 
et al 2002). In a large trial, comprising more than 1600 
patients, the incidence of renal toxicity was 9.3% for pami-
dronate and 10.7% for zoledronic acid (Rosen et al 2001). In 
this clinical trial, renal deterioration occurred in 6.7%–10% 
of patients treated with a 2-hour infusion of pamidronate, 
depending on the renal toxicity deﬁ  nition.
Known pamidronate complications are fever/pyrexia, 
nausea, emesis, fatigue, headache, hypocalcemia, hypophos-
phatemia, hypomagnesemia, lymphocytopenia, thrombocy-
topenia, rigidity, arthralgia, and myalgia. In addition, local 
injection site skin reactions including pain, redness, swelling, 
indurations, phlebitis, and thrombophlebitis are described. 
Serious complications, occurring in less than 2% of patients, 
include acute systemic inflammatory reaction, ocular 
inﬂ  ammation, renal failure, nephritic syndrome, electrolyte 
imbalance, and osteonecrosis of the maxilla and mandible 
(Migliorati et al 2006; Tanvetyanon and Stiff 2006).
Some recently published articles suggest that the risk 
of renal deterioration may not increase signiﬁ  cantly when 
pamidronate is infused over 1 hour (Tyrell et al 1994). The 
results of the 1-hour comparator trial including 80 multiple 
myeloma patients conducted by de Lemos and colleagues 
(2007) suggest that the prevalence of renal deterioration was 
not signiﬁ  cantly different in patients treated with a 2-hour 
infusion. Reducing pamidronate administration time would 
also help to reduce the average cost per treatment, and the 
waiting list, and beneﬁ  t quality of life for the patient.
Based on early data on the safety of shorter pamidronate 
infusion time, patients with multiple myeloma at the out-
patient clinic in Uddevalla were given 1-hour infusions 
from year 2003.
Method
Study design
This retrospective study, from 2003 to April 2007, included 
all patients treated with pamidronate, who had multiple 
myeloma and no pre-existing renal impairment. The study 
was performed in the Hematology Section of Uddevalla 
Hospital, Sweden. S-creatinine (S-Cr), S-calcium (S-Ca) or 
S-free ionized calcium, and S-albumin before and during the 
pamidronate treatment were recorded.
Assessments
Renal deterioration during the treatment was deﬁ  ned as 
S-Cr increase 44.2 μmol/L or as an increase 2 times the 
baseline if baseline S-Cr was 124 μmol/L. For those patients 
with baseline S-Cr 124 μmol/L, renal deterioration during 
the treatment was deﬁ  ned as S-Cr increase 88.4 μmol/L, 
or as an increase 2 times the baseline. Our laboratory has 
as total S-Ca reference value the range 2.32–2.62 (mmol/L). 
Baseline S-Cr or S-Ca was deﬁ  ned as the value reported 
closest to the time of the ﬁ  rst pamidronate dose within the 
3 months before that dose. We assessed the increase of S-Cr 
and S-Ca after each treatment, and for each patient.
Statistical analysis
Standard statistical methods were employed. Mean values 
and standard deviation (±SD) are reported. The difference 
between means was tested with Student’s t test and the non 
parametric Mann-Whitney test when needed. Differences 
between the results in our study and comparable trials 
were tested with Fisher’s exact test and chi square test. 
The difference between means was considered statistically 
signiﬁ  cant if p  0.05.
Results
We identiﬁ  ed 79 patients who had undergone pamidronate 
90 mg therapy, and who had no pre-existing renal impairment. 
Their mean age was 68 years and 63% of patients were 
men. The mean number of pamidronate cycles per patient was 
10.7. The number of infusions with evaluable data concerning 
S-Cr, adverse effects such as S-Ca, or S-free ionized calcium 
were 793, 846, and 669 respectively. The S-Cr and total S-Ca 
before treatment, also called the baseline, were 99.8 μmol/L 
and 2.53 mmol/L respectively. The difference in baseline 
S-Cr between the sexes was signiﬁ  cant (Table 1).
Renal deterioration
The prevalence of renal deterioration between 2 pamidronate 
infusions was 2.2% for the total population and 0.8% for 
women (not statistically signiﬁ  cant difference). S-Cr increase 
at least between 2 pamidronate infusions was observed in 8.9% 
of the patients. The distribution of renal impairment between 
the sexes was similar; 5 men and 2 women (Table 2).
Analyzing the cause of creatinine increase in those 
7 patients revealed that in 3 patients the increase was a Therapeutics and Clinical Risk Management 2008:4(6) 1373
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Table 1 Patient demographics, number of pamidronate cycles per patient, and baseline creatinine and calcium concentrations (mean ± SD, 
range within parenthesis)
Total Female Male
No of pat. identiﬁ  ed 79 29 (37%) 50 (63%)
Mean age at diagnosis (years) 68 ± 10.4 (38–88) 70 ± 8.7 (53–86) 67 ± 11.1 (38–88)
No. of pamidronate cycles/no pat. 10.7 ± 7.1 (1–31) 8.8 ± 5.8 (1–25) 11.8 ± 7.6 (1–31)
S-Cr (μmol/L) 99.8 ± 37.8 (52–267) 87 ± 23.7a (52–160) 107.5 ± 42.7a(54–267)
Total S-Ca (mmol/L) 2.53 ± 0.19 (2.24–3.02) 2.51 ± 0.14 (2.24–2.94) 2.54 ± 0.21 (2.24–3.02)
aThe difference in baseline S-Cr between the two sexes is signiﬁ  cant (p  0.03).
Abbreviations: S-Cr, serum creatinine; S-Ca, serum calcium.
Table 2 Events of serum creatinine increase, infusion related events (inclusive adverse, exclusive osteonecrosis of the jaw), hypocalcemia 
(2.32 mmol/L) such as S-Cr and S-Ca range under treatment in 79 patients with multiple myeloma given one hour pamidronate 90 mg 
infusion. For each parameter, the number of infusions with evaluable data are used
Total Female Male
S-Cr increasing events/no infusions 17/790 2.2% 2/245 0.8% 15/545 2.8%
S-Cr increasing events/no patients 7/79 8.9% 2/29 6.9% 5/50 10%
S-Cr range during treatment (μmol/L) 37–333 37–175 44–333
Events related to the infusion/no infusions 7/846 0.8% 2/256 0.8% 5/590 0.9%
Events related to the infusion/no patients 6/79 7.6% 2/29 6.9% 4/50 8%
Hypocalcemia events/no infusions 69/669 10.3% 8/209 3.8% 61/460 13.3%
Hypocalcemia events/no patients 28/79 35.4% 6/29 20.7% 22/50 44%
S-Ca range during treatment (mmol/L) 2.09–3.94 2.18–3.94 2.09–3.28
Abbreviations: S-Cr, serum creatinine; S-Ca, serum calcium.
result of progress of the disease, and that in 2, it resulted 
from opportunistic infections. In the remaining 2 patients 
no obvious cause could be found, and the interpretation 
was that pamidronate-induced renal impairment was 
probable. These two patients received 10 and 26 infusions, 
respectively.
Adverse effects
The infusions of pamidronate were tolerated well. No 
fatal or life-threatening events occurred. Previously 
described adverse effects of pamidronate excluded 
osteonecrosis of the jaw, but included other events related 
to infusion (hypertension), observed in 0.8% of infusions 
or 7.6% of patients. One male patient was diagnosed with 
osteonecrosis of the jaw after less than 10 pamidronate 
cycles (Table 2).
Hypocalcemia
During therapy, the minimum values recorded of S-Ca 
and S-free ionized calcium were 2.09 and 1.13 mmol/L, 
respectively. The mean total S-Ca was 0.05 mmol/L, lower 
than the baseline total S-Ca (Table 2).
Pamidronate therapy failure
The incidence of this newly introduced term for pamidronate 
therapy, demonstrated as persistent hypercalcemia after two 
consecutive infusions, was 1.3%. This value reduced to 0.9% 
when patients with progression of multiple myeloma disease 
were excluded.
Discussion
The 1-hour 90 mg pamidronate infusion for patients with 
multiple myeloma, and no pre-existing renal impairment, 
was shown to be safe from the risk of nephrotoxicity and 
pamidronate induced hypocalcemia, and was well tolerated, 
in accordance with the present pamidronate therapy guidelines 
(Lacy et al 2006; Kyle et al 2007). Renal deterioration occurred 
in 8.9% of the 79 patients. The proportion of the events related 
to infusion, including wzzell-known infusion-related adverse 
effects, was approximately 10% and the incidence of therapy 
failure was 1.3%. The comparator study conducted by de 
Lemos and colleagues (2007) showed that renal deterioration 
occurred in 15% of patients, and that the median increase in 
S-Cr was 13%. The difference in renal deterioration between 
our and the comparator study is not signiﬁ  cant (p = 0.343).Therapeutics and Clinical Risk Management 2008:4(6) 1374
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Pamidronate’s efﬁ  cacy is also demonstrated in our trial by 
the low incidence of pamidronate therapy failure, deﬁ  ned as 
persistent tumor-induced hypercalcemia after two infusions 
in a row, independent of the progression status of multiple 
myeloma disease.
During the pamidronate treatment a trend towards a 
decrease in S-Cr was observed. No patients showed any 
clinical symptoms related to hypocalcemia. Comparison of 
the baseline mean, and mean during treatment, of S-Cr for 
each patient in our study population showed no signiﬁ  cant 
reduction in S-Cr. However, further clinical trials are needed 
to fully investigate this observation. We assume that the low 
incidence of nephrotoxicity in our study population is due to 
the careful choice of patients for the decreased pamidronate 
infusion, based on previous studies, our clinical experience, 
and recommendations concerning the indications, dose-
optimization, and duration of pamidronate therapy.
Because males are slightly more commonly affected by 
multiple myeloma, they normally represent a larger group in 
a study population. The other factor that contributed to fewer 
females in the study was our intention to treat with a lower dose 
individuals with low weight, based on our clinical experience. 
The careful selection of female individuals rather than the 
fewer pamidronate cycles at 8.8 compared to 11.8 (statistically 
insigniﬁ  cant difference) in men is thought to have contributed 
to the differences in prevalence of renal deterioration such as 
in the percentage of the reduction of S-Cr between the two 
sexes. Renal impairment developed in 6.9% of women and 
10% of men, but a reduction of more than 30% of baseline 
S-Cr occurred in 3.5% of women and 8% of men.
In conclusion, monthly infusions of pamidronate are an 
effective adjunctive treatment to palliate the destructive skeletal 
events often occuring in patients with multiple myeloma. One 
hour’s treatment with 90 mg of pamidronate in patients with 
no pre-existing renal impairment is proved to be safe and well 
tolerated, and to improve patient comfort and well-being. 
Our retrospective trial showed that reducing the infusion 
time from 4 hours to 1 hour caused no signiﬁ  cant increase in 
nephrotoxicity, hypocalcemia, and adverse effects.
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